$0.66
-0.02 (-2.97%)
Open$0.68
Previous Close$0.68
Day High$0.72
Day Low$0.66
52W High$4.49
52W Low$1.48
Volume—
Avg Volume70.1K
Market Cap131.84M
P/E Ratio—
EPS$-0.37
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+2,945.2% upside
Current
$0.66
$0.66
Target
$20.19
$20.19
$14.44
$20.19 avg
$28.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 14.90M | 15.53M | 15.53M |
| Net Income | 2.54M | 3.35M | 2.88M |
| Profit Margin | 17.0% | 21.6% | 18.5% |
| EBITDA | 5.18M | 5.39M | 5.26M |
| Free Cash Flow | 2.62M | 3.23M | 2.70M |
| Rev Growth | -8.5% | -1.6% | +3.5% |
| Debt/Equity | 0.17 | 0.17 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |